Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced locoregional melanoma

Annals of Surgery

Volumn 249, Issue 6, 2009, Pages 1008-1013

  Kroon, Hidde M ^a,c   Lin, D Yin ^a   Kam, Peter C A ^a,b   Thompson, John F ^a,b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MELANOMA INSTITUTE AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DACTINOMYCIN; MELPHALAN; TROPISETRON;

AGED; ARTICLE; BLISTER; CANCER SURVIVAL; DRUG INFUSION; EDEMA; ERYTHEMA; FEMALE; HUMAN; ISOLATED LIMB INFUSION; LIMB PERFUSION; LIMB TUMOR; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MORBIDITY; NAUSEA AND VOMITING; PRIORITY JOURNAL; TISSUE INJURY; TUMOR RECURRENCE; ADULT; AGE; ARM; CANCER INVASION; COHORT ANALYSIS; HYPERTHERMIC THERAPY; INTRAARTERIAL DRUG ADMINISTRATION; LEG; METHODOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; REGIONAL PERFUSION; RETROSPECTIVE STUDY; SKIN TUMOR; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ARM; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COHORT STUDIES; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; INFUSIONS, INTRA-ARTERIAL; LEG; MALE; MELANOMA; MIDDLE AGED; NEOPLASM INVASIVENESS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 67649201895     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181a77ce5     Document Type: Article

References (37)

1. Hall HI, Miller DR, Rogers JD, et al. Update on the incidence and mortality from melanoma in the United States. J Am Acad Dermatol. 1999;40:35-42.
2. Van Etten B, van Geel AN, de Wilt JH, et al. Fifty tumor necrosis factorbased isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors. Ann Surg Oncol. 2003;10:32-37.
3. Noorda EM, Vrouenraets BC, Nieweg OE, et al. Safety and efficacy of isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol. 2002;9:968-974.
4. McMasters KM. Isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol. 2002;9:939-940.
5. Vrouenraets BC, Nieweg OE, Kroon BBR. Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg. 1996;83:1319-1328.
6. Vrouenraets BC, Klaase JM, Nieweg OE, et al. Toxicity and morbidity of isolated limb perfusion. Semin Surg Oncol. 1998;14:224-231.
7. Polanczyk CA, Marcantonio E, Goldman L, et al. Impact of age on perioperative complications and length of stay in patients undergoing noncardiac surgery. Ann Intern Med. 2001;134:637-643.
8. Thompson JF, Kam PC, Waugh RC, et al. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol. 1998;14:238-247.
9. Kroon HM, Moncrieff M, Kam PC, et al. Outcomes following isolated limb infusion for melanoma: a 14-year experience. Ann Surg Oncol. 2008;15: 3003-3013.
10. Lindnér P, Thompson JF, De Wilt JH, et al. Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanoma. Eur J Surg Oncol. 2004;30:433-439.
11. Klaase JM, Kroon BBR, van Geel AN, et al. Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion. J Am Coll Surg. 1994;178:564-572.
12. Thompson JF, Kam PC. Isolated limb infusion for melanoma: a simple but effective alternative to isolated limb perfusion. J Surg Oncol. 2004;1:1-3.
13. Wieberdink J, Benckhuysen C, Braat RP, et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1982;18:905-910.
14. Thompson JF, Hunt JA, Shannon KF, et al. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg. 1997;132: 903-907.
15. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatments. Geneva, Switzerland: World Health Organization; 1979. WHO Offset publication 48.
16. Zenilman ME. Surgery in the elderly. Curr Probl Surg. 1998;35:99-179.
17. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet. 2005;365:687-701.
18. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-3648.
19. Morton DL, Thompson JF, Cochran AJ, et al; MSLT-group. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307-1317.
20. Eggermont AM. Treatment of melanoma in-transit metastases confined to the limb. Cancer Surv. 1996;26:335-349.
21. Vrouenraets BC, Eggermont AM, Hart AA, et al. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor-alpha versus toxicity after melphalan alone. Eur J Surg Oncol. 2001;27:390-395.
22. Fletcher WS, Pommier R, Small K. Results of cisplatin hyperthermic isolation perfusion for stage IIIA and IIIAB extremity melanoma. Melanoma Res. 1994;4(suppl. 1):17-19.
23. Hoekstra HJ, Schraffordt Koops H, de Vries LG, et al. Toxicity of hyperthermic isolated limb perfusion with cisplatin for recurrent melanoma of the lower extremity after previous perfusion treatment. Cancer. 1993;72:1224-1229.
24. Shiu MH, Knapper WH, Fortner JG, et al. Regional isolated limb perfusion of melanoma intransit metastases using mechlorethamine (nitrogen mustard). J Clin Oncol. 1986;4:1819-1826.
25. Bonenkamp JJ, Thompson JF, de Wilt JH, et al. Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence. Eur J Surg Oncol. 2004;30:1107-1112.
26. Knorr C, Meyer T, Janssen T, et al. Hyperthermic isolated limb perfusion (HILP) in malignant melanoma: experience with 101 patients. Eur J Surg Oncol. 2006;32:224-227.
27. Sanki A, Kam PC, Thompson JF. Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology. Ann Surg. 2007;245:591-596.
28. Klaase JM, Kroon BB, Van Geel BN, et al. Patient- and treatment-related factors associated with acute regional toxicity alter isolated perfusion for melanoma of the extremities. Am J Surg. 1994;167:618-620.
29. Kroon HM, Moncrieff M, Kam PC, et al. Determinants of acute regional limb toxicity following isolated limb infusion for melanoma. Eur J Surg Oncol. 2008;34:1105-1106.
30. Klaase JM, Kroon BB, Beijnen JH, et al. Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb. Br J Cancer. 1994;70:151-153.
31. Beasley GM, Petersen RP, Yoo J, et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol. 2008; 15:2195-2205.
32. Vrouenraets BC, Klaase JM, Kroon BBR, et al. Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs: the influence of acute regional toxic reactions. Arch Surg. 1995;130:43-47.
33. Thompson JF, Kam PCA, de Wilt JHW. Isolated limb infusion for melanoma. In: Thompson JF, Morton DL, Kroon BB, eds. Textbook of Melanoma. London: Martin Dunitz; 2004:429-437.
34. Sonneveld EJ, Vrouenraets BC, van Geel BN, et al. Systemic toxicity after isolated limb perfusion with melphalan for melanoma. Eur J Surg Oncol. 1996;22:521-527.
35. Sear JW, Rosewarme F. Anaesthesia for surgeons. In: Morris PJ, Malt RA, eds. Oxford Textbook of Surgery. New York, NY: Oxford University Press; 1994:53-82.
36. Leung JM, Dzankic S. Relative importance of preoperative health status versus intraoperative factors in predicting postoperative adverse outcomes in geriatric surgical patients. J Am Geriatr Soc. 2001;49:1080-1085.
37. Schwarz RE, Karpeh MS, Brennan MF. Factors predicting hospitalization after operative treatment for gastric carcinoma in patients older than 70 years. J Am Coll Surg. 1997;184:9-15.